Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

882 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia.
Mateos MK, Trahair TN, Mayoh C, Barbaro PM, Sutton R, Revesz T, Barbaric D, Giles JE, Alvaro F, Mechinaud F, Catchpoole D, Kotecha RS, Dalla-Pozza L, Quinn MCJ, MacGregor S, Chenevix-Trench G, Marshall GM. Mateos MK, et al. Among authors: giles je. Thromb Res. 2019 Jun;178:132-138. doi: 10.1016/j.thromres.2019.04.011. Epub 2019 Apr 11. Thromb Res. 2019. PMID: 31030032
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD; Australian and New Zealand Children's Oncology Group. Sutton R, et al. Among authors: giles je. Br J Haematol. 2009 Aug;146(3):292-9. doi: 10.1111/j.1365-2141.2009.07744.x. Epub 2009 Jun 3. Br J Haematol. 2009. PMID: 19500099 Free article. Clinical Trial.
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
Sutton R, Venn NC, Law T, Boer JM, Trahair TN, Ng A, Den Boer ML, Dissanayake A, Giles JE, Dalzell P, Mayoh C, Barbaric D, Revesz T, Alvaro F, Pieters R, Haber M, Norris MD, Schrappe M, Dalla Pozza L, Marshall GM. Sutton R, et al. Br J Haematol. 2018 Feb;180(4):550-562. doi: 10.1111/bjh.15056. Epub 2017 Nov 30. Br J Haematol. 2018. PMID: 29194562 Free article.
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia.
Mateos MK, Marshall GM, Barbaro PM, Quinn MCJ, George C, Mayoh C, Sutton R, Revesz T, Giles JE, Barbaric D, Alvaro F, Mechinaud F, Catchpoole D, Lawson JA, Chenevix-Trench G, MacGregor S, Kotecha RS, Dalla-Pozza L, Trahair TN. Mateos MK, et al. Among authors: giles je. Haematologica. 2022 Mar 1;107(3):635-643. doi: 10.3324/haematol.2020.268565. Haematologica. 2022. PMID: 33567813 Free PMC article.
Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion.
Venn NC, van der Velden VH, de Bie M, Waanders E, Giles JE, Law T, Kuiper RP, de Haas V, Mullighan CG, Haber M, Marshall GM, Md N, van Dongen JJ, Sutton R. Venn NC, et al. Among authors: giles je. Leukemia. 2012 Jun;26(6):1414-6. doi: 10.1038/leu.2011.348. Epub 2011 Dec 9. Leukemia. 2012. PMID: 22157735 Free PMC article. No abstract available.
Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.
Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, Budgen B, Bahar AY, Malec M, Sykes PJ, Kuss BJ, Waters K, Venn NC, Giles JE, Haber M, Norris MD, Marshall GM, Morley AA. Brisco MJ, et al. Among authors: giles je. J Mol Diagn. 2009 May;11(3):194-200. doi: 10.2353/jmoldx.2009.080047. Epub 2009 Mar 26. J Mol Diagn. 2009. PMID: 19324994 Free PMC article.
882 results